Nat Commun :武汉大学徐永镇团队在脊肌萎缩症的次要剪接调控研究取得新进展

2020-11-07 Bio生物世界 Bio生物世界

脊髓性肌萎缩症(Spinal Muscular Atrophy, SMA)是一类主要由SMN基因缺陷引起的运动神经元变性和肌肉萎缩遗传性疾病,在我国新生儿中的患病率为1/10000-1/6000。

脊髓性肌萎缩症(Spinal Muscular Atrophy, SMA)是一类主要由SMN基因缺陷引起的运动神经元变性和肌肉萎缩遗传性疾病,在我国新生儿中的患病率为1/10000-1/6000。

与患上SMA的病人类似,SMN基因缺陷型小鼠和果蝇也都呈现出运动神经元和肌肉发育缺陷。尽管主要(U2-type)和次要(U12-type)剪接体的组装都需要SMN蛋白,但次要剪接对SMN的缺失更为敏感。然而已有研究都集中在SMN基因,脊髓性肌萎缩症的下游致病基因和次要剪接调控机制一直未有充分探索。

2020年11月5日,武汉大学生命科学学院徐永镇/樊玉杰团队在脊髓性肌萎缩症相关的次要剪接调控和功能研究中取得新成果。该成果以:Defective minor spliceosomes induce SMA-associated phenotypes through sensitive intron-containing neural genes in Drosophila 为题,发表于 Nature Communications 杂志。

为更深入地研究、理解脊髓性肌萎缩症,研究团队首先利用基因组编辑技术精确地在果蝇体内分别敲除了次要剪接体的两个RNA组分:U12和U6atac snRNA。这两种突变体均表现出典型的运动神经元发育和运动能力缺陷,直接证明次要剪接缺陷即可导致SMA表型。

随后开展了突变体和野生型的转录组测序,借助自主设计开发的生物信息学方法,发现除了以往预测的19个U12型内含子,果蝇基因组中至少还存在250多个次要剪接敏感的剪接位点和48个敏感内含子,涉及33个神经功能相关基因。此后通过大量遗传学筛选,发现回补其中3个基因—Zmynd10, Pcyt2, Fas3—可以有效地拯救SMN缺陷导致的SMA表型。

另外,研究团队还发现众多的敏感性剪接位点可以被次要剪接体和主要剪接体竞争性识别,揭示出一种新的内含子选择性识别和剪接机制。

因此,该项研究显着地拓宽了次要剪接体识别和催化的内含子范围,鉴定出3个果蝇SMA发病下游基因,为研究人类SMA疾病提供了新的靶点与更高效准确的分析方法。

近年来,研究团队取得的成果包括人类血液肿瘤疾病中SF3B1高频突变导致RNA紊乱的分子机制(Genes Dev, 2016)、保守内含子元件促进反式剪接发生的新机制(Genes Dev, 2015)、转录与剪接的双向偶联机制(NAR, 2020)等。未来团队将围绕RNA剪接参与的发育与疾病等生理病理进程,继续开展深入研究。

博士生李梁为论文的第一作者,博士生丁展、庞亭林协助开发了新的生物计算方法,徐永镇教授与樊玉杰副研究员为共同通讯作者。该研究获得了国家自然科学基金委杰出青年科学基金、重大研究计划和面上项目资助。

原始出处:

Liang Li, Zhan Ding, Ting-Lin Pang,et al.Defective minor spliceosomes induce SMA-associated phenotypes through sensitive intron-containing neural genes in Drosophila.Nat Commun. 2020 Nov 5;11(1):5608. doi: 10.1038/s41467-020-19451-z.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087818, encodeId=85dc208e818dd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 17 03:15:12 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884785, encodeId=64611884e8545, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 03 21:15:12 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695953, encodeId=1065169595305, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Fri Jan 01 09:15:12 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503155, encodeId=1920150315568, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Mon Nov 09 12:15:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087818, encodeId=85dc208e818dd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 17 03:15:12 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884785, encodeId=64611884e8545, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 03 21:15:12 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695953, encodeId=1065169595305, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Fri Jan 01 09:15:12 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503155, encodeId=1920150315568, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Mon Nov 09 12:15:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2021-07-03 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087818, encodeId=85dc208e818dd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 17 03:15:12 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884785, encodeId=64611884e8545, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 03 21:15:12 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695953, encodeId=1065169595305, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Fri Jan 01 09:15:12 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503155, encodeId=1920150315568, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Mon Nov 09 12:15:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2021-01-01 chendoc252
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087818, encodeId=85dc208e818dd, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 17 03:15:12 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884785, encodeId=64611884e8545, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 03 21:15:12 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695953, encodeId=1065169595305, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Fri Jan 01 09:15:12 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503155, encodeId=1920150315568, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Mon Nov 09 12:15:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]

相关资讯

Science Advances :孙进团队对阿霉素进行改造,对于肿瘤治疗有更好的益处

大多数抗肿瘤药物缺乏与纳米载体的亲和力,导致药物载量低(通常少于10%),胶体稳定性差以及全身循环中药物过早泄漏。此外,如何实现肿瘤特异性药物释放也是纳米递送系统设计的一个挑战。

Angew Chem Int Ed Engl :人参根部土壤细菌分泌的根瘤菌素,被发现可治疗老年痴呆症

人参,作为一种传统的中医药材,的确是一味滋补药,适用于调整血压、恢复心脏功能、神经衰弱以及身体虚弱等症状。

盘点:近期鼻炎治疗小结

【1】Molecules:冬虫夏草菌丝培养提取物(Cs-4)对变应性鼻炎和哮喘模型鼠的抗炎作用

盘点:近期听力损失治疗小结

【1】JAMA Otolaryngol Head Neck Surg:单侧耳蜗植入治疗重度、深度或中度倾斜至深度双侧感音神经性听力损失:系统性的回顾和共识陈述

拯救偏头痛!CGRP抑制剂的发现之路

靶向CGRP或其受体的单克隆抗体和小分子拮抗剂已经对偏头痛产生了很大的影响,但它们有潜力做得更多。

盘点:近期前列腺癌治疗研究小结

【1】Prostate Cancer P D:恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件